Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
S-Biomedics currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. ZHU, JIANJIAN is the busiest examiner for the company, with 1 pending office action.
The distribution of 2 pending office actions across 2 distinct art units suggests that S-Biomedics is pursuing multiple technical paths within the Biotechnology & Pharmaceuticals sector. Each of the 2 distinct examiners is responsible for one of the pending actions. This means ZHU, JIANJIAN handles half of the current workload.
Practitioners must manage two separate prosecution tracks. Since there are 2 distinct examiners and 2 distinct art units, the company may encounter different examination styles. The strategy for S-Biomedics involves balancing the requirements of these 2 pending office actions to secure patent protection across its biotechnology interests. This distributed approach provides a broader base for patent acquisition compared to a single-action portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
| FONTAINHAS, AURORA M | 1 | 37.8% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275289 | METHOD FOR INDUCING AND PREPARING RETINAL OUTER LAYER CELLS FROM STEM CELLS, AND COMPOSITION FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING CELLS PREPARED THEREBY | ZHU, JIANJIAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275289 | METHOD FOR INDUCING AND PREPARING RETINAL OUTER LAYER CELLS FROM STEM CELLS, AND COMPOSITION FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING CELLS PREPARED THEREBY | ZHU, JIANJIAN | — |
| 17884021 | COMPOSITIONS FOR TREATING ISCHEMIC DISEASES OR NEUROINFLAMMATORY DISEASES CONTAINING NEURAL PROGENITOR CELLS OR SECRETOME THEREOF AS ACTIVE INGREDIENT | FONTAINHAS, AURORA M | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275289 | METHOD FOR INDUCING AND PREPARING RETINAL OUTER LAYER CELLS FROM STEM CELLS, AND COMPOSITION FOR PREVENTING OR TREATING RETINAL DISEASES, CONTAINING CELLS PREPARED THEREBY | ZHU, JIANJIAN | 1631 | §103§112 | Final Rejection | — | Pending | Aug 01, 2023 |
| 17884021 | COMPOSITIONS FOR TREATING ISCHEMIC DISEASES OR NEUROINFLAMMATORY DISEASES CONTAINING NEURAL PROGENITOR CELLS OR SECRETOME THEREOF AS ACTIVE INGREDIENT | FONTAINHAS, AURORA M | 1675 | §103 | Final Rejection | — | Pending | Aug 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialS-Biomedics has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jianjian Zhu has the most, with 1 of S-Biomedics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
